Group 1 - The National Healthcare Security Administration (NHSA) is set to adjust the National Medical Insurance Drug List in 2026, focusing on aligning with current healthcare fund capabilities and drug supply situations [1] - Traditional Chinese medicines with unclear adverse reaction labels will be prioritized for removal from the list [1] - The adjustment process will emphasize transparency and scientific evaluation, ensuring fairness and clarity in the rationale and criteria for changes [1] Group 2 - The newly released "Reference Drug Pre-communication Method (Trial)" optimizes the evaluation rules for new drug applications [2] - Reference drugs serve as benchmarks for assessing the value of new drugs during negotiations, influencing pricing outcomes [2] - The new method allows eligible innovative drugs to apply for reference drug status earlier, facilitating better preparation of economic and clinical data for subsequent evaluations [2]
医保药品目录将优化评审规则
Xin Lang Cai Jing·2026-02-11 21:49